Browse by author
Lookup NU author(s): Professor Andrew Pearson, Professor Alan Boddy
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Although both cyclophosphamide (CP) and ifosfamide (IF) are used in the treatment of central nervous system tumors, little is known about the concentration of either drug or their metabolites in the cerebrospinal fluid (CSF) of children. The concentrations of the parent oxazaphosphorine and its principal metabolites were measured simultaneously in the plasma and CSF of 25 children. Twenty-one patients received CP for the treatment of either acute lymphoblastic leukemia, non-Hodgkin's lymphoma, or medulloblastoma, and 4 children received IF for the treatment of rhabdomyosarcoma. A high degree of interpatient variation was seen in terms of the CSF concentration of CP and the CSF:plasma ratio. The CSF:plasma ratio was greater for IF than for CP (P < 0.001). In contrast to IF, where the majority of metabolites was measured in the CSF, no child receiving CP had detectable metabolites. Children receiving dexamethasone had lower concentrations of CP in the CSF (P = 0.04). The CSF:plasma ratio for isophosphoramide mustard was greater than that for either parent drug or any other metabolite. These results demonstrate that IF enters the CSF to a greater extent than CP in children. The ability of both IF and CP and their metabolites to cross the blood-brain barrier may be reduced by dexamethasone.
Author(s): Yule, S., Price, L., Pearson, A. D. J., Boddy, A. V.
Publication type: Article
Publication status: Published
Journal: Clinical Cancer Research
Year: 1997
Volume: 3
Issue: 11
Pages: 1985-1992
Print publication date: 01/11/1997
ISSN (print): 1078-0432
ISSN (electronic):
URL: http://cat.inist.fr/?aModele=afficheN&cpsidt=2060230
PubMed id: 9815588
